Nom du produit:4-bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile
IUPAC Name:4-bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile
- CAS:2068065-05-2
- Formule moléculaire:C8H4BrN3O
- Pureté:95%+
- Numéro de catalogue:CM325559
- Poids moléculaire:238.04
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:2068065-05-2
- Formule moléculaire:C8H4BrN3O
- Point de fusion:-
- Code SMILES:N#CC1=C2C(Br)=CC(O)=CN2N=C1
- Densité:
- Numéro de catalogue:CM325559
- Poids moléculaire:238.04
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Pyrazolopyridines
- Over the past few years, many pyrazole fused-ring systems, especially with applications in medicinal chemistry, have been published. These include general structures such as pyrazoline, pyrazoline, pyrazoquinoline, pyrazoloisoquinoline, pyrazoline, pyrazolopyrazine, pyrazolopyrazine, pyranopyrazole, pyrano Pyrazoles, pyrazolotriazines and pyrazole fused phosphorus rings.
Column Infos
- Selpercatinib
- The FDA has granted accelerated approval to selpercatinib (Retevmo; Eli Lilly and Company) for pediatric patients aged 2 years and older with RET-altered metastatic thyroid cancer or solid tumors, the federal agency announced in a press release. Selpercatinib is a highly selective, potent RET inhibitor. It works by blocking a type of enzyme (kinase) and helps prevent the cancer cells from growing.